Clinical Trials Logo

Squamous Cell Carcinoma of Skin clinical trials

View clinical trials related to Squamous Cell Carcinoma of Skin.

Filter by:
  • None
  • Page 1

NCT ID: NCT04913220 Active, not recruiting - Malignant Melanoma Clinical Trials

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Start date: July 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: - To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with cemiplimab - To assess other indicators of antitumor activity - To assess the concentrations of SAR444245 when given in combination with cemiplimab - To assess the immunogenicity of SAR444245 - To assess active concentrations of cemiplimab when given in combination with SAR444245

NCT ID: NCT02321982 Withdrawn - Clinical trials for Basal Cell Carcinoma

Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery

Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether separate- versus same-day preoperative consultation affects time to treatment (start to finish), utilization rate of Mohs, rate of case cancellations, cost, and patient satisfaction. The investigators hypothesize that patients with same-day preoperative consultation will have a shorter time between cancer diagnosis and removal but, only when coordination of care is needed, longer time between removal and consultation with other specialists, as compared to patients with separate-day consultation. The investigators anticipate that patients with same-day preoperative consultation will have a decrease in travel cost as compared to patients with separate-day consultation. The investigators expect that there will be no difference in various satisfaction matters between groups, with the exception of potentially greater convenience reported by patients in the same-day preoperative consultation group. Finally, the investigators hypothesize that there will be no difference between groups in regards to rates of surgery cancellation.

NCT ID: NCT02218164 Completed - Clinical trials for Carcinoma, Squamous Cell

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Start date: August 12, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in patients with squamous cell carcinoma of the skin. Specifically, investigators want to determine if the combination of 5-FU/Capecitabine (oral pills) and Interferon alpha-2b (injection) can help people with advanced cases of squamous cell carcinoma of the skin. For participants that are not approved for oral capecitabine, treating physicians will use continuous infusion 5-FU. Both 5-FU/Capecitabine and Interferon alpha-2b have been used separately to treat squamous cell carcinoma of the skin and are FDA approved in other cancer types.